Madrid, Spain, U.S., October 26, 2026
Lamassu Biotech has presented initial safety and pharmacokinetic findings from the ongoing first-in-human Phase 1/2a clinical trial of SA53, an investigational oral MDM2 inhibitor being developed for patients with advanced solid tumors. The results were presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, highlighting progress in the development of targeted cancer therapies designed to reactivate the body’s natural tumor-suppression mechanisms. Across four dose-escalation cohorts, ranging from 0.054 to 0.44 mg/kg/day on a three-day dosing schedule, the company reported no dose-limiting toxicities, no treatment-emergent adverse events of Grade 2 or higher, and no serious adverse events. SA53 also achieved plasma drug exposures that exceeded levels predicted by nonclinical pharmacokinetic and pharmacodynamic modeling to be pharmacologically active. These early observations are relevant because previous MDM2 inhibitors have encountered development challenges associated with dose-dependent blood-related toxicities, particularly thrombocytopenia, or low platelet counts. However, the initial findings involve only four patients across the reported dose levels, with one patient per cohort. The results are preliminary and do not establish the safety or effectiveness of SA53 in a larger patient population.
SA53 Targets the MDM2-p53 Cancer Pathway
SA53 is an investigational small-molecule drug designed to selectively inhibit MDM2, a protein that regulates the activity of the tumor-suppressor protein p53. Under normal conditions, p53 helps cells respond to DNA damage and other forms of cellular stress by regulating processes such as cell-cycle arrest, DNA repair, and programmed cell death. In many cancers, the p53 pathway is impaired, allowing abnormal cells to survive and proliferate. In certain tumors that retain functional, wild-type p53, excessive MDM2 activity can suppress this natural defense mechanism. Blocking the interaction between MDM2 and p53 may restore p53 activity and promote the elimination of cancer cells. This biological rationale makes MDM2 an important target in oncology drug development, particularly for selected tumors with wild-type TP53. Lamassu is investigating whether SA53 can achieve potentially active drug exposure while maintaining a tolerable safety profile. Although the mechanism provides a scientific basis for further research, the extent to which SA53 can produce meaningful tumor responses in patients remains under investigation. The drug is not approved for clinical use, and its potential role will depend on results from ongoing and future clinical studies.
Early Safety and Pharmacokinetic Findings
The Phase 1/2a study, identified as LB-SA53-101, is evaluating SA53 in patients with locally advanced or metastatic solid tumors, including tumors with wild-type p53. In the reported dose-escalation experience, platelet count reductions remained Grade 1 or lower, while neutrophil counts remained within normal limits in all reported patients. These observations are notable because bone marrow and blood-cell toxicities have historically limited the development of some drugs targeting the MDM2-p53 pathway. The company also reported that the maximum plasma concentration of SA53 increased approximately in proportion to the administered dose across the cohorts. Drug exposure at the current dose level exceeded the levels predicted by preclinical modeling to be pharmacologically active. These pharmacokinetic findings help researchers understand how the investigational compound behaves in the body and inform decisions about further dose escalation. Nevertheless, absence of significant toxicity in four patients cannot rule out less common, delayed, or dose-dependent adverse effects. Continued monitoring in additional participants will be essential to establish the treatment’s tolerability and identify an appropriate dose range for subsequent clinical development.
Phase 1/2a Trial Continues Dose Escalation
Lamassu Biotech is continuing the dose-escalation portion of the multicenter Phase 1/2a trial to determine the maximum tolerated dose and recommended Phase 2 dose of SA53. Researchers will continue evaluating safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity as more patients enter the study. The dose-escalation process is intended to help investigators identify a dose that provides suitable drug exposure without unacceptable toxicity. The subsequent Phase 2a portion is expected to further assess the candidate’s safety and explore its potential activity in selected patient populations. Lamassu is developing SA53 as part of its broader focus on targeted small-molecule therapies for oncology and other areas of unmet medical need. The company’s latest findings represent an early development milestone, particularly given the historical challenges associated with MDM2 inhibitors. The next important milestones will be continued dose escalation, identification of a recommended Phase 2 dose, and the emergence of interpretable clinical activity data. Until larger studies provide further evidence, SA53 remains investigational, and its potential benefits for patients with cancer are not yet established.
Source: Lamassu Biotech press release



